Abstract
An antisense oligonucleotide that targets the Hippo pathway protein YAP1, long thought “undruggable,” has shown preclinical promise and is under evaluation in a phase I trial.
©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.